75000 - Document - Cover page
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Document - Audit Information
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - Consolidated Balance Sheets
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - Consolidated Balance Sheets (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - Consolidated Statements of Operations and Comprehensive Loss
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - Consolidated Statements of Stockholders’ Equity
link:presentationLink
link:calculationLink
link:definitionLink
75070 - Statement - Consolidated Statement of Stockholders’ Equity (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75080 - Statement - Consolidated Statements of Cash Flows
link:presentationLink
link:calculationLink
link:definitionLink
995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance
link:presentationLink
link:calculationLink
link:definitionLink
995467 - Disclosure - Description of the Business
link:presentationLink
link:calculationLink
link:definitionLink
995477 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995487 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures
link:presentationLink
link:calculationLink
link:definitionLink
995497 - Disclosure - Collaborative Research and Development Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995507 - Disclosure - Sale of Future Royalties
link:presentationLink
link:calculationLink
link:definitionLink
995517 - Disclosure - Fair Value Measurements and Available for Sale Investments
link:presentationLink
link:calculationLink
link:definitionLink
995527 - Disclosure - Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
995537 - Disclosure - Equity Incentive Plans
link:presentationLink
link:calculationLink
link:definitionLink
995547 - Disclosure - Employee Benefit Plan
link:presentationLink
link:calculationLink
link:definitionLink
995557 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995567 - Disclosure - Segment Reporting
link:presentationLink
link:calculationLink
link:definitionLink
995577 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995587 - Disclosure - Subsequent Event
link:presentationLink
link:calculationLink
link:definitionLink
995597 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995607 - Disclosure - Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995617 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995627 - Disclosure - Collaborative Research and Development Agreements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995637 - Disclosure - Sale of Future Royalties (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995647 - Disclosure - Fair Value Measurements and Available for Sale Investments (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995657 - Disclosure - Stockholders' Equity (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995667 - Disclosure - Equity Incentive Plans (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995677 - Disclosure - Commitments and Contingencies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995687 - Disclosure - Segment Reporting (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995697 - Disclosure - Income Taxes (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995707 - Disclosure - Description of the Business (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995717 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995727 - Disclosure - Summary of Significant Accounting Policies - Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share (Details)ies (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995737 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Property and Equipment, Net (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995747 - Disclosure - Balance Sheet Accounts and Supplemental Disclosures - Schedule of Accrued Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995757 - Disclosure - Collaborative Research and Development Agreements - Narrative (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995767 - Disclosure - Collaborative Research and Development Agreements - Schedule of Milestone Achieved (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995777 - Disclosure - Collaborative Research and Development Agreements - Schedule of Milestone Achieved (Parenthetical) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995787 - Disclosure - Sale of Future Royalties - Narrative (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995797 - Disclosure - Sale of Future Royalties - Schedule of Royalty Transaction Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995807 - Disclosure - Sale of Future Royalties - Schedule of Royalty Transaction Activity (Parenthetical) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995817 - Disclosure - Fair Value Measurements and Available for Sale Investments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995827 - Disclosure - Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995837 - Disclosure - Fair Value Measurements and Available for Sale Investments - Available-for-sale Investments (Parenthetical) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995847 - Disclosure - Fair Value Measurements and Available for Sale Investments - Schedule of Unrealized Loss and Fair Values in a Loss Position (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995857 - Disclosure - Fair Value Measurements and Available for Sale Investments - Narrative (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995867 - Disclosure - Stockholders' Equity - Narrative (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995877 - Disclosure - Stockholders' Equity - Schedule Of Stock Repurchase Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995887 - Disclosure - Equity Incentive Plans - Narrative (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995897 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations under Operating Leases (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995907 - Disclosure - Equity Incentive Plans - Schedule of Activity Related to Stock Option Awards (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995917 - Disclosure - Equity Incentive Plans - Schedule of Time-based Restricted Stock Units & PSU's (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995927 - Disclosure - Equity Incentive Plans - Schedule of Grant Date Fair Value Assumptions (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995937 - Disclosure - Equity Incentive Plans - Schedule of Weighted Average Assumptions used to Estimate Fair Value (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995947 - Disclosure - Equity Incentive Plans - Schedule of Non-cash Stock-based Compensation Expense (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995957 - Disclosure - Equity Incentive Plans - Schedule of Non-cash Stock-based Compensation Expense (Parenthetical) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995967 - Disclosure - Employee Benefit Plan (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995977 - Disclosure - Commitments and Contingencies - Narrative (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995987 - Disclosure - Commitments and Contingencies - Schedule of Non-Cancellable Office Lease Costs (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995997 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Annual Obligations (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996007 - Disclosure - Segment Reporting - Narrative (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996017 - Disclosure - Segment Reporting - Schedule of Revenue by Major Customers by Reporting Segments (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996027 - Disclosure - Income Taxes - Schedule of Loss before Income Tax Provision (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996037 - Disclosure - Income Taxes - Narrative (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996047 - Disclosure - Income Taxes - Deferred tax assets and liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996057 - Disclosure - Income Taxes - Reconciliation of Taxes at Federal Statutory Rate to Provision For (Benefit From) Income Taxes (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996067 - Disclosure - Income Taxes - Reconciliation of Taxes at Federal Statutory Rate to Provision For (Benefit From) Income Taxes (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
996077 - Disclosure - Income Taxes - Unrecognized tax benefits (Details)
link:presentationLink
link:calculationLink
link:definitionLink
999009 - Disclosure - Anchoring
link:presentationLink
link:calculationLink
link:definitionLink
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Released (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Forfeitures and cancellations (in dollars per share)
Jemperli Royalty Monetization Agreement, Milestone Two
Jemperli Royalty Monetization Agreement, Milestone Two [Member]
Jemperli Royalty Monetization Agreement, Milestone Two
Segments [Domain]
Segments [Domain]
Zejula Revenue
Zejula Revenue [Member]
Zejula Revenue
Income (Loss) from Continuing Operations before Income Taxes, Foreign
Foreign
First Installment
First Installment [Member]
By the end of 2026
License Agreement, Centessa Pharmaceuticals (UK) Limited
License Agreement, Centessa Pharmaceuticals (UK) Limited [Member]
License Agreement, Centessa Pharmaceuticals (UK) Limited
Deferred Tax Assets, Gross [Abstract]
Deferred Tax Assets:
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Preferred Stock, Shares Issued
Preferred stock, shares issued (in shares)
Third Commercial Sales Milestone
Third Commercial Sales Milestone [Member]
Third commercial sales milestone
Proceeds From Advance Future Royalties
Proceeds From Advance Future Royalties
Proceeds from sale of future royalties
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Non-cash investing and financing activities:
Phase 3 Clinical Trial Initiation - First Indication
Phase 3 Clinical Trial Initiation - First Indication [Member]
Phase 3 clinical trial initiation - first indication
Common Stock, Capital Shares Reserved For Future Issuance, Increase
Common Stock, Capital Shares Reserved For Future Issuance, Increase
Capital shares reserved for future issuance, increase (in shares)
Exclusive License Agreement
Exclusive License Agreement [Member]
Exclusive License Agreement
Shares Acquired, Average Cost Per Share
Average price paid per share (in dollars per share)
Plan Name [Axis]
Plan Name [Axis]
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer
12 Months or Greater, Fair Value
Equity [Abstract]
Equity [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
US Government Agencies Debt Securities [Member]
Agency securities
Operating Expenses [Abstract]
Operating expenses:
Fair Value, Inputs, Level 2 [Member]
Significant Other Observable Inputs (Level 2)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted-Average Exercise Price per Share
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Payments Of Advance Future Royalties Issuance Costs
Payments Of Advance Future Royalties Issuance Costs
Payments for issuance costs related to the sale of future royalties
Common Stock, Shares Authorized
Common stock, shares authorized (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested
Aggregate intrinsic value, outstanding
Effective Income Tax Rate Reconciliation, Nondeductable Compensation, Amount
Effective Income Tax Rate Reconciliation, Nondeductable Compensation, Amount
Non-deductible compensation, Amount
Product and Service [Axis]
Product and Service [Axis]
Document Fiscal Period Focus
Document Fiscal Period Focus
Revenue from Contract with Customer [Abstract]
Entity Shell Company
Entity Shell Company
Second Installment
Second Installment [Member]
During 2027
Segment Reporting, Policy [Policy Text Block]
Segment Reporting
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted-average number of shares outstanding:
First Commercial Sales Milestone
First Commercial Sales Milestone [Member]
First commercial sales milestone
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Common Stock, Shares, Issued
Common stock, shares issued (in shares)
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Statement [Table]
Statement [Table]
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Increase related to current year tax positions
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted average grant date fair value per share (in dollars per share)
Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff
Acquired in-process research and development
Statement [Line Items]
Statement [Line Items]
Treasury Stock, Value, Acquired, Cost Method
Approximate dollar value of shares purchased (in dollars per share)
Revenue from Contract with Customer [Policy Text Block]
Revenue Recognition
Entity Filer Category
Entity Filer Category
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Restricted Stock Units
Reimbursement Payments to Acquire Productive Assets
Reimbursement Payments to Acquire Productive Assets
Reimbursement
Liabilities and Equity
Total liabilities and stockholders’ equity
Effective Income Tax Rate Reconciliation, Tax Contingency, Percent
Effective Income Tax Rate Reconciliation, Tax Contingency, Percent, Total
Change in unrecognized tax benefits, Percent
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Stock options exercisable, ending balance (in dollars per share)
Long-Lived Tangible Asset [Axis]
Property and Equipment, Net Type [Axis]
Operating Loss Carryforwards [Table]
Operating Loss Carryforwards [Table]
Pennsylvania New Jersey Texas and City of Philadelphia [Member]
Pennsylvania New Jersey Texas and City of Philadelphia.
Pennsylvania, New Jersey, Texas and City of Philadelphia
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Cash and Cash Equivalents, Fair Value Disclosure
Fair Value included in cash and cash equivalents
Deferred Tax Assets, Valuation Allowance
Less: valuation allowance
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
Income taxes at statutory rates, Percent
Shares Issued, Price Per Share
Share price (in dollars per share)
Zejula Royalty Monetization Agreement
Zejula Royalty Monetization Agreement [Member]
Zejula Royalty Monetization Agreement
Cybersecurity Risk Management Third Party Engaged [Flag]
Documents Incorporated by Reference [Text Block]
Documents Incorporated by Reference
Phase 2 Clinical Trial Initiation [Member]
Phase 2 Clinical Trial Initiation [Member]
Phase 2 clinical trial initiation
Effective Income Tax Rate Reconciliation, Percent
Effective Income Tax Rate Reconciliation, Percent, Total
Income tax expense reconciliation, Percent
Options to purchase common stock
Income Tax Jurisdiction [Axis]
Income Tax Jurisdiction [Axis]
Debt Securities, Available-for-Sale, Noncurrent
Long-term investments
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay
Employer match, percent of employees' gross pay
Tax Year 2018 and Prior
Tax Year 2018 and Prior [Member]
2018 and after
Net Sales Royalty Threshold
Net Sales Royalty Threshold
Royalty sales
Annual Rent Increase Percent
Annual Rent Increase Percent
Increase in annual rent (as a percent)
Capitalized and Amortized Period
Capitalized and amortized period..
Capitalized and amortized period.
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation
Net share settlement of restricted stock units
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Property, Plant and Equipment [Line Items]
Property and Equipment, Net [Line Items]
Commercial Sales Milestone [Member]
Commercial sales milestone.
Commercial sales first exceed $100.0 million
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Granted (in shares)
Disaggregation of Revenue [Table]
Disaggregation of Revenue [Table]
Rosnilimab
Rosnilimab [Member]
Rosnilimab
Cybersecurity Risk Management, Strategy, and Governance [Table]
First Marketing Authorization Application Approval - Second Indication
First Marketing Authorization Application Approval - Second Indication [Member]
First MAA approval - second indication
ANB032
ANB032 [Member]
ANB032
Stock awards
Share-Based Payment Arrangement [Member]
Earnings Per Share, Basic
Basic (in dollars per share)
Retirement Benefits [Text Block]
Employee Benefit Plan
Advance Future Royalties, Aggregate Payment, Threshold
Advance Future Royalties, Aggregate Payment, Threshold
Royalties and milestones, agreement amount to be received
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Ending balance (in shares)
Beginning balance (in shares)
Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]
Schedule of Available-for-sale Investments
Debt, Policy [Policy Text Block]
Debt Issuance Costs
Liabilities, Current
Total current liabilities
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Lessee, Operating Lease, Liability, to be Paid, Year Five
2030
Liabilities Related To Sale Of Future Royalties
Liabilities Related To Sale Of Future Royalties [Table]
Liabilities Related To Sale Of Future Royalties [Table]
Domestic Tax Jurisdiction [Member]
Federal tax authority
Federal
Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale
Sales and maturities of investments
Effective Income Tax Rate Reconciliation [Table]
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions
Increase related to prior year tax positions
Receivables For Stock Options Exercised
Receivables For Stock Options Exercised
Receivable related to issuance of common stock, upon exercise of stock options
Equity, Attributable to Parent [Abstract]
Stockholders’ equity:
Entity Small Business
Entity Small Business
LesseeOperatingLeaseTerminationFee
LesseeOperatingLeaseTerminationFee
Lessee, operating lease, termination fee
Noncash Interest Expense, Negative Amortization
Noncash Interest Expense, Negative Amortization.
Non-cash interest expense capitalized
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Equity compensation
Monthly base rate (usd per sqft)
Rent Per Square Foot
Rent Per Square Foot
Nature of Operations [Text Block]
Description of the Business
Entity Well-known Seasoned Issuer
Entity Well-known Seasoned Issuer
Number Of Financial Institutions Utilized For Diversification Of Funds
Number Of Financial Institutions Utilized For Diversification Of Funds
Number of banks utilized for diversification of funds (in banks)
Employee Stock Purchase Plan, 2017 [Member]
Employee Stock Purchase Plan, 2017 [Member]
Employee Stock Purchase Plan, 2017
Sale of Stock, Price Per Share
Offering share price (in dollars per share)
Laboratory equipment
Laboratory Equipment [Member]
Laboratory Equipment [Member]
Share-Based Payment Arrangement [Text Block]
Equity Incentive Plans
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Sagard Healthcare Royalty Partners, LP
Sagard Healthcare Royalty Partners, LP [Member]
Sagard
Sale Of Future Royalties Text Block
Sale Of Future Royalties Text Block [Text Block]
Sale of Future Royalties
Lessee, Lease, Description [Line Items]
Lessee, Lease, Description [Line Items]
Amendment Flag
Amendment Flag
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Share Ratio
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Share Ratio
Equivalent shares
Product and Service [Domain]
Product and Service [Domain]
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Income taxes at statutory rates, Amount
Chief Executive Officer [Member]
Chief Executive Officer
Earnings Per Share, Policy [Policy Text Block]
Net Loss Per Common Share
Liabilities and Equity [Abstract]
LIABILITIES AND STOCKHOLDERS’ EQUITY
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Net Cash Provided by (Used in) Operating Activities
Net cash provided by (used in) operating activities
Number of Businesses after Spinoff
Number of businesses after spinoff.
Number of business independent
Increase (Decrease) in Operating Lease Liability
Operating lease liabilities
Period of transactions increasing ownership of stockholders
Period of transactions increasing ownership of stockholders
Advance Future Royalties, Liability, Noncurrent
Advance Future Royalties, Liability, Noncurrent
Liability related to sale of future royalties
Common Stock [Member]
Common Stock
Accounting Standards Update and Change in Accounting Principle [Table]
New Accounting Pronouncements or Change in Accounting Principle [Table]
Cybersecurity Risk Role of Management [Text Block]
Tax Credit Carryforward, Amount
Research tax credit carryforwards
Defined Contribution Plan, Employer Discretionary Contribution Amount
Employer contributions to the plan
Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]
Schedule of Milestones Achieved
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Granted (in dollars per share)
Lessee, Operating Lease, Liability, to be Paid, Year Three
2028
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Less: accumulated depreciation and amortization
Debt Securities, Available-for-Sale [Line Items]
Debt Securities, Available-for-sale [Line Items]
Entity Address, Address Line One
Entity Address, Address Line One
Deferred Tax Liabilities, Gross
Total deferred tax liabilities
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of Weighted Average Assumptions used to Estimate Fair Value
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Axis]
Earnings Per Share [Abstract]
Net loss per common share:
Income Tax, Policy [Policy Text Block]
Income Taxes
GlaxoSmithKline
GlaxoSmithKline [Member]
GSK
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Foreign Currency of Foreign Operations
Name of Property [Axis]
Name of Property [Axis]
Operating Lease, Right-of-Use Asset
Operating ROU assets
Operating lease right-of-use assets
Debt Securities, Available-for-Sale, Unrealized Loss Position
Fair Value
Deferred Tax Assets, Gross
Total deferred tax assets
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Purchase of investments
Payments to Acquire Debt Securities, Available-for-Sale
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Unrealized (loss) gain on available for sale securities
Document Type
Document Type
Income Taxes Paid, Net
Total
Income taxes paid, net of refunds received
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Entity Central Index Key
Entity Central Index Key
Advance Future Royalties, Liabilities
Advance Future Royalties, Liabilities
Ending balance
Beginning balance
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Net increase (decrease) in cash and cash equivalents
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Options to purchase common stock (in shares)
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Related Disclosures [Abstract]
Stock Repurchased and Retired During Period, Shares
Repurchases and retirements of common stock (in shares)
Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]
Schedule of Performance Shares, Outstanding Activity
APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition
Stock-based compensation
Filing of MMA - Second Indication
Filing of MMA - Second Indication [Member]
Filing of the first MAA - second indication
Advance Future Royalties, Liability
Advance Future Royalties, Liability [Policy Text Block]
Liability Related to the Sale of Future Royalties
Advance Future Royalties, Issuance Costs
Advance Future Royalties, Issuance Costs
Issuance costs related to the sale of future royalties
Common Stock, Par or Stated Value Per Share
Common stock, par value (in dollars per share)
Security Deposit
Security deposit
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Comprehensive income (loss)
Operating Lease, Right-of-Use Asset, Periodic Reduction
Amortization of right-of-use assets – operating
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted average remaining contractual term, options outstanding
Debt Securities, Available-for-Sale, Amortized Cost
Amortized Cost
Debt Securities, Available-for-Sale
Total Fair Value
Fair Value included in short-term or long-term investments
ANB101
ANB101 [Member]
ANB101
Document Financial Statement Error Correction [Flag]
Document Financial Statement Error Correction
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Exercises (in shares)
Regulatory Approval For Marketing Of The First Licensed Product In The EU [Member]
Regulatory approval for marketing of the first licensed product in the EU .
Regulatory approval for marketing of the first licensed product in the EU
Accrued Liabilities, Current
Accrued expenses
Total accrued expenses
Current Fiscal Year End Date
Current Fiscal Year End Date
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount
Employer match, maximum contributions
Entity Address, State or Province
Entity Address, State or Province
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Number of shares, ending balance (in shares)
Number of shares, beginning balance (in shares)
Liabilities Related To Sale Of Future Royalties
Liabilities Related To Sale Of Future Royalties [Roll Forward]
Liabilities Related To Sale Of Future Royalties [Roll Forward]
Asset Acquisition [Domain]
Asset Acquisition [Domain]
Preferred Stock, Shares Outstanding
Preferred stock, shares outstanding (in shares)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Gross Unrealized Gains
Research and Development Expense, Policy [Policy Text Block]
Research and Development Expenses
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation
Net share settlement of restricted stock units (in shares)
Contract with Customer, Timing of Satisfaction of Performance Obligation and Payment
Milestone revenue recognition
Amortization Of Advance Future Royalties Issuance Costs
Amortization Of Advance Future Royalties Issuance Costs
Amortization of issuance costs
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount
State income tax, net of federal benefit, Amount
License [Member]
License
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Other, Amount
Other, Amount
Comprehensive Income, Policy [Policy Text Block]
Comprehensive Income (Loss)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Schedule of Components of Deferred Tax Assets and Liabilities
Collaborative Arrangement Disclosure [Text Block]
Collaborative Research and Development Agreements
Performance Shares [Member]
PSU
Asset Acquisition, Contingent Consideration Arrangements, Range of Outcomes, Value, High
Asset Acquisition, Contingent Consideration Arrangements, Range of Outcomes, Value, High
Potential future payments
Open Market Sales Agreement
Open Market Sales Agreement [Member]
Open Market Sales Agreement
Marketable Securities, Policy [Policy Text Block]
Short Term and Long Term Investments
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized
Number of additional shares authorized
Deferred Tax Assets, Tax Credit Carryforwards, Research
Research and development credits
Other Assets, Noncurrent
Other long-term assets
Jemperli Royalty Monetization Agreement Amendment One
Jemperli Royalty Monetization Agreement Amendment One [Member]
Jemperli Royalty Monetization Agreement Amendment 1
Debt Securities, Available-for-Sale, Current
Short-term investments
Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards [Line Items]
Equity Incentive Plan, 2017 [Member]
Equity Incentive Plan, 2017 [Member]
Equity Incentive Plan, 2017
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. [Member]
Vanda
State and Local Jurisdiction [Member]
State tax authority
State
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
Schedule of Non-cash Stock-based Compensation Expense
Commercial And Corporate Obligations [Member]
Commercial And Corporate Obligations [Member]
Commercial and corporate obligations
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Gain (Loss)
Noncash Advance Future Royalties, Interest Expense
Noncash Advance Future Royalties, Interest Expense
Non-cash interest expense for the sale of future royalties
Non-cash interest expense for the sale of future royalties
Non-cash interest expense
Non-cash interest expense
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Deferred Tax Assets, Research And Development
Deferred Tax Assets, Research And Development
Section 174 Capitalized R&D
Share-based Compensation Arrangement by Share-based Payment Award, Options And Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award, Options And Employee Stock Purchase Plan
Issuance of common stock from exercises of options and employee stock purchase plan (in shares)
Proceeds From Sale Of Advance Future Royalties
Proceeds From Sale Of Advance Future Royalties
Proceeds from the sale of future royalties
Preferred Stock, Value, Issued
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at December 31, 2025 and December 31, 2024, respectively
Minimum [Member]
Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Granted (in dollars per share)
Financial Instrument [Axis]
Financial Instrument [Axis]
Assets, Current [Abstract]
Current assets:
LesseeOperatingLeaseTerminationPeriod
Lessee operating lease termination period.
Lessee, operating lease, termination period (in months)
Net Sales Royalty, Percent
Net Sales Royalty, Percent
Royalty percent on net sales
Fair Value, Inputs, Level 3 [Member]
Significant Unobservable Inputs (Level 3)
Segment Reporting [Abstract]
Deferred Tax Liabilities, Property, Plant and Equipment
Fixed assets
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis
Tax Period [Domain]
Tax Period [Domain]
Unrealized Gain (Loss) on Investments
Accretion/amortization of investments, net
Liabilities, Current [Abstract]
Current liabilities:
Royalty Management Company [Member]
Royalty management company.
Royalty Management
Stock Repurchased and Retired During Period, Value
Repurchases and retirements of common stock
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued
Issued under ESPP (in shares)
Revenue Recognition, Milestone, Annual Sales Threshold
Revenue Recognition, Milestone, Annual Sales Threshold
Annual sales milestone threshold
Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]
Schedule of Unrealized Loss and Fair Values in a Loss Position
Operating Loss Carryforwards
Net operating loss carryforwards
Lessee, Operating Lease, Renewal Term
Lease renewal term (in years)
Transaction Service [Member]
Transaction service.
Transaction Service
Proceeds from stock plans
Proceeds from Stock Plans
Lessee, Leases [Policy Text Block]
Leases
Collaborative Arrangement, Payment
Collaborative Arrangement, Payment
Payment for existing drug supply
Upfront payment
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Weighted average grant date fair value, ending balance (in dollars per share)
Weighted average grant date fair value, beginning balance (in dollars per share)
General and Administrative Expense [Member]
General and administrative
Operating Lease, Liability
Total
Auditor Firm ID
Auditor Firm ID
Advance Future Royalties, Liability, Noncurrent, Net
Advance Future Royalties, Liability, Noncurrent, Net
Net of proceeds
Sale of Stock, Percentage of Ownership after Transaction
Percentage rate of transactions increasing ownership of stockholders
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]
Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value
Filing of Biologics License Application - First Indication
Filing of Biologics License Application - First Indication [Member]
Filing of the first BLA - first indication
Noncash Advance Future Royalties And Amortization Of Advance Future Royalties, Interest Expense
Noncash Advance Future Royalties And Amortization Of Advance Future Royalties, Interest Expense
Non-cash interest expense for the sale of future royalties
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]
Lessee, Lease, Description [Table]
Lessee, Lease, Description [Table]
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Valuation allowance, Percent
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms
Weighted average remaining contractual term, other than options outstanding (in years)
AUSTRALIA
Australia
Capital Expenditures Incurred but Not yet Paid
Amounts accrued for property and equipment
Proceeds From Issuance Of Public Offering
Proceeds From Issuance Of Public Offering
Proceeds from public offerings, net of underwriters' fees
Second Commercial Sales Milestone
Second Commercial Sales Milestone [Member]
Second commercial sales milestone
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Weighted Average Number of Shares Outstanding, Basic
Basic (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number
Number of shares, Restricted stock units expected to vest (in shares)
First Biologics License Application Approval D M M R E C
First Biologics License Application Approval D M M R E C [Member]
First BLA approval - first indication
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Aggregate intrinsic value, options exercisable
Advance Future Royalties, Retained Rights After Annual Sales Threshold Exceeded
Advance Future Royalties, Retained Rights After Annual Sales Threshold Exceeded
Rights retained
Deferred Tax Liabilities, Leasing Arrangements
ROU asset
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Unrealized loss position for greater than 12 months
12 Months or Greater, Gross Unrealized Losses
Segments [Axis]
Segments [Axis]
Long-Lived Tangible Asset [Domain]
Property and Equipment, Net Type [Domain]
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Asset Acquisition, Consideration Transferred, Transaction Cost
Transaction costs incurred
Deferred Tax Asset, Interest Carryforward
Interest
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Foreign tax effects valuation allowance, Amount
Change in the valuation allowance, Amount
Equity, Attributable to Parent
Stockholders' equity, ending balance
Stockholders' equity, beginning balance
Total stockholders’ equity
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value (in dollars per share)
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation
Statement of Stockholders' Equity [Abstract]
Statement of Stockholders' Equity [Abstract]
Noncash Interest Expense Recognized
Noncash Interest Expense Recognized
Non-cash interest expense recognized
Other Liabilities Disclosure [Abstract]
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
FDA Regulatory Approval For Marketing Of First Licensed Product In The USA For The Treatment Of Active Flares In GPP [Member]
FDA regulatory approval for marketing of first licensed product in the USA for the treatment of active flares in GPP.
FDA regulatory approval for marketing of first licensed product in the USA for the treatment of active flares in GPP
Collaborative Arrangement [Member]
Collaborative Research and Development Agreement
In Vivo Toxicology Studies [Member]
In Vivo Toxicology Studies [Member]
Initiated in vivo toxicology studies using good laboratory practices (GLPs)
Leasehold Improvements [Member]
Leasehold improvements
Entity Address, Address Line Two
Entity Address, Address Line Two
Fair Value Disclosures [Text Block]
Fair Value Measurements and Available for Sale Investments
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]
Schedule of Grant Date Fair Value Assumptions
U.S.
UNITED STATES
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Shares Subject to Options
Percentge Rate of Federal Net Operating Losses Carryforwards Future Taxable Income
Percentge Rate of Federal Net Operating Losses Carryforwards Future Taxable Income
Future taxable income
Schedule of Accrued Liabilities [Table Text Block]
Schedule of Accrued Expenses
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
Schedule of Activity Related to Unrecognized Tax Benefits
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Plan Name [Domain]
Plan Name [Domain]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mutual Fund [Member]
Mutual funds
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Remaining Contractual Terms
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Remaining Contractual Terms
Weighted average remaining contractual term, other than options vested and expected to vest (in years)
Repayment Of Advance Future Royalty And Milestones
Repayment Of Advance Future Royalty And Milestones
Royalty and milestone payments to Sagard
Principal repayment of liability for sale of future royalties
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Certificates of Deposit [Member]
Certificates of Deposit
Certificates of deposit
Tax Period [Axis]
Tax Period [Axis]
Share-based Compensation Arrangement by Share-based Payment Award, Common Share Equivalent
Share-based Compensation Arrangement by Share-based Payment Award, Common Share Equivalent
Award equivalent shares
Share of common stock
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
Other, Amount
Foreign Tax Jurisdiction [Member]
Foreign tax authority
Foreign
Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment
Area of Real Estate Property
Area of leased property (sqft)
Entity Address, City or Town
Entity Address, City or Town
Number of Reportable Segments
Number of reportable segments
Security Exchange Name
Security Exchange Name
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Other, Percent
Property, Plant and Equipment, Gross
Property and equipment, gross
Counterparty Name [Axis]
Counterparty Name [Axis]
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Loss before income taxes
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Cash and cash equivalents, end of period
Cash and cash equivalents, beginning of period
Interest Paid, Excluding Capitalized Interest, Operating Activities
Interest portion of repayment for sale of future royalties
Statistical Measurement [Domain]
Statistical Measurement [Domain]
Assets, Current
Total current assets
Share-Based Payment Arrangement, Expense
Total
Non-cash stock-based compensation expense
Document Period End Date
Document Period End Date
Title and Position [Axis]
Title and Position [Axis]
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV [Domain]
ICFR Auditor Attestation Flag
ICFR Auditor Attestation Flag
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Stock options exercisable, ending balance (in shares)
Statement of Financial Position [Abstract]
Statement of Financial Position [Abstract]
Restricted Stock Units (RSUs) [Member]
RSUs
Deferred Tax Liabilities Royalty Monetization
Deferred Tax Liabilities Royalty Monetization
Royalty monetization
Cumulative Milestones Recognized
Cumulative Milestones Recognized [Member]
Milestones recognized through December 31, 2025
LesseeOperatingLeaseExpirationPeriod
Lessee operating lease expiration period.
Lease termination term (in years)
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Security, Excluded EPS Calculation [Table]
AnaptysBio-generated Anti-PD-1 (Jemperli/Dostarlimab)
AnaptysBio-generated Anti-PD-1 (Jemperli/Dostarlimab) [Member]
PD-1 (Jemperli/Dostarlimab)
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Financial Instruments [Domain]
Financial Instruments [Domain]
Jemperli Royalty Monetization Agreement, Milestone One
Jemperli Royalty Monetization Agreement, Milestone One [Member]
Jemperli Royalty Monetization Agreement, Milestone One
Centessa Pharmaceuticals (UK) Limited (Centessa)
Centessa Pharmaceuticals (UK) Limited (Centessa) [Member]
Centessa
Lessee, Operating Lease, Liability, to be Paid, Year Two
2027
Deferred Revenue Arrangement, by Type [Table]
Deferred Revenue Arrangement, by Type [Table]
DRI Healthcare Trust
DRI Healthcare Trust [Member]
DRI Healthcare Trust
Property, Plant and Equipment, Impairment [Policy Text Block]
Long Lived Assets
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Less than 12 Months, Gross Unrealized Losses
Weighted Average Number of Shares Outstanding, Diluted
Diluted (in shares)
Entity File Number
Entity File Number
Operating Loss Carry forwards Annual Limitations
Operating Loss Carry forwards Annual Limitations
Operating loss carry forwards annual limitations
Cover [Abstract]
Cover [Abstract]
Royalty Agreement, Above $1. 5 billion Below $2.5 Billion
Royalty Agreement, Above $1. 5 billion Below $2.5 Billion [Member]
Royalty Agreement, Above $1. 5 billion Below $2.5 Billion
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Accounts payable and other liabilities
Accrued Common Stock Repurchased
Accrued Common Stock Repurchased
Accrued for repurchase of common stock
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Forfeitures and cancellations (in shares)
Supplemental Balance Sheet Disclosures [Text Block]
Balance Sheet Accounts and Supplemental Disclosures
US Treasury Securities [Member]
US Treasury Securities
Number of Operating Segments
Number of operating segments
Sale of Stock [Domain]
Sale of Stock [Domain]
Segment Reporting Disclosure [Text Block]
Segment Reporting
General and Administrative Expense
General and administrative
10770 Wateridge Circle, San Diego, California 92121
10770 Wateridge Circle, San Diego, California 92121 [Member]
Lease Agreement
Internal Expenses
Internal Expenses [Member]
Internal
Stock Issued During Period, Value, Options and Employee Stock Purchase Plan
Stock Issued During Period, Value, Options and Employee Stock Purchase Plan
Issuance of common stock from exercises of options and employee stock purchase plan
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
Forfeitures and cancellations (in shares)
Deferred Tax Assets, Other
Other, net
Share Repurchase Program, Expiration Date
Repurchase program expiration date
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value
Property, Plant and Equipment, Useful Life
Property and equipment, useful life (in years)
New Accounting Pronouncements, Policy [Policy Text Block]
Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]
Schedule of Future Minimum Annual Obligations
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Other, Percent
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Award vesting period (in years)
Advance Future Royalties, Interest Rate, Effective Percentage
Advance Future Royalties, Interest Rate, Effective Percentage
Effective interest rate
Increase (Decrease) in Contract with Customer, Asset
Receivables from collaborative partners
Income (Loss) from Continuing Operations before Income Taxes, Domestic
U.S.
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Interest or penalties on uncertain tax benefits
Lessee, Operating Lease, Term of Contract
Lease term (in months)
Common Stock, Shares, Outstanding
Stockholders' equity, ending balance (in shares)
Stockholders' equity, beginning balance (in shares)
Common stock, shares outstanding (in shares)
Operating Lease, Liability, Current
Current portion of operating lease liability
Depreciation, Depletion and Amortization
Depreciation and amortization
Cybersecurity Risk Management Processes Integrated [Flag]
Document Transition Report
Document Transition Report
Deferred Tax Assets, Net
Deferred tax assets, net of valuation allowance
Operating Expenses
Total operating expenses
Royalty Agreement
Royalty Agreement [Member]
Royalty Agreement
Payments for Repurchase of Common Stock
Payments for repurchase of common stock
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
Schedule of Reconciliation of Taxes at Federal Statutory Rate to Provision for (Benefit from) Income Taxes
Royalty Agreement, Above $2.5 billion
Royalty Agreement, Above $2.5 billion [Member]
Royalty Agreement, above $2.5 billion
Statement of Cash Flows [Abstract]
Statement of Cash Flows [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-Average Grant Date Fair Value
Stock Issued During Period, Value, New Issues
Issuance of common stock, net of $6,516 of transaction costs
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Schedule of Activity Related to Stock Option Awards
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent
Equity compensation, Percent
Equity [Text Block]
Stockholders' Equity
Payments Of Stock Issuance Costs And Underwriting Discounts And Commissions
Payments Of Stock Issuance Costs And Underwriting Discounts And Commissions
Underwriting discounts and commissions and offering expenses
Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Unrecognized tax benefits that if recognized and realized would affect the effective tax rate
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
Schedule of Time-based Restricted Stock Units Activity
Deferred Tax Liabilities, Other
Other, net
Cybersecurity Risk Management Processes Integrated [Text Block]
Net loss
Net loss
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Aggregate intrinsic value, options outstanding
Cumulative Repayment Of Advance Future Royalty And Milestones
Cumulative Repayment Of Advance Future Royalty And Milestones
Royalties and milestones received
Revenue Recognition, Milestone Method, Commercial Sale Or Expiration Of Patents, Agreement Term
Revenue Recognition, Milestone Method, Commercial Sale Or Expiration Of Patents, Agreement Term
Agreement term following first commercial sale or expiration of the last to expire patent (in years)
Operating Lease, Cost
Operating lease cost
Tangible Asset Impairment Charges
Long-lived asset impairment charges
Royalty Agreement, Above $1. 0 billion Below $1.5 Billion
Royalty Agreement, Above $1. 0 billion Below $1.5 Billion [Member]
Royalty Agreement, Above $1. 0 billion Below $1.5 Billion
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Expected dividend yield
Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period
Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period
Number of milestones achieved during period
Operating Lease, Payments
Cash paid for amounts included in the measurement of lease liabilities
Assets [Abstract]
ASSETS
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-free interest rate
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other assets
Noncash Interest Expense Capitalized
Noncash Interest Expense Capitalized
Non-cash interest expense capitalized
Name of Property [Domain]
Name of Property [Domain]
Document Fiscal Year Focus
Document Fiscal Year Focus
First Marketing Authorization Application Approval First Indication
First Marketing Authorization Application Approval First Indication [Member]
First MAA approval - first indication
Net Cash Provided by (Used in) Investing Activities [Abstract]
CASH FLOWS FROM INVESTING ACTIVITIES:
Retirement Benefits [Abstract]
Retirement Benefits [Abstract]
Accounts Payable, Current
Accounts payable
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
Schedule of Loss before Income Tax Provision
Research and Development Expense [Member]
Research and development
Accrued Research And Development Expenses, Current
Accrued Research And Development Expenses, Current
Accrued research, development and manufacturing expenses
Defined Contribution Plan, Employer Matching Contribution, Percent of Match
Employer match, percent of contributions
Noncash Advance Future Royalties, Interest Expense
Noncash Advance Future Royalties, Interest Expense [Policy Text Block]
Non-Cash Interest Expense on the Liability Related to the Sale of Future Royalties
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
Schedule of Royalty Transaction Activity
Research Tax Credit Carryforward [Member]
Research tax credit carryforwards
Unrecognized Tax Benefits [Roll Forward]
Unrecognized Tax Benefits [Roll Forward]
Proceeds from Stock Options Exercised
Proceeds from issuance of common stock
Proceeds from stock options exercised
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Weighted Average Grant Date Fair Value
Weighted average grant date fair value , Restricted stock units expected to vest (in dollars per share)
Lessee, Operating Lease, Liability, to be Paid, Year One
2026
Sale of Stock, Consideration Received on Transaction
Net proceeds received from transaction
Effective Income Tax Rate Reconciliation [Line Items]
Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding
Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding
Annual increase in number of shares available for issuance percentage (as a percent)
Advance Future Royalties, Annual Sales Threshold
Advance Future Royalties, Annual Sales Threshold
Royalties agreement, maximum annual royalty payout capacity
Lessee, Operating Lease, Liability, to be Paid, after Year Five
Thereafter
Share-Based Payment Arrangement [Abstract]
Share-based Payment Arrangement [Abstract]
Preclinical And Other Unallocated Costs
Preclinical And Other Unallocated Costs [Member]
Preclinical and other unallocated costs
Sale of Stock [Axis]
Sale of Stock [Axis]
Net Cash Provided by (Used in) Investing Activities
Net cash provided by investing activities
Imsidolimab
Imsidolimab [Member]
Imsidolimab
Available-for-sale Debt Securities, Remaining Maturity
Available-for-sale Debt Securities, Remaining Maturity
Remaining maturity (in years)
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Schedule of Segment Reporting Information, by Segment [Table]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount
Equity compensation, Amount
Share Repurchase Program, Remaining Authorized, Amount
Remaining repurchase amount
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Forfeitures and cancellations (in dollars per share)
Money Market Funds [Member]
Money market funds
Revenue Recognition, Milestone Method, Contingent
Revenue Recognition, Milestone Method, Contingent
Milestones that may be recognized in the future
Income Tax Disclosure [Text Block]
Income Taxes
Debt Securities, Available-for-Sale, Allowance for Credit Loss
Allowance for credit losses
Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
Filing of MMA - First Indication
Filing of MMA - First Indication [Member]
Filing of the first MAA - first indication
Property, Plant and Equipment [Table Text Block]
Schedule of Property and Equipment, Net
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Ending balance (in dollars per share)
Beginning balance (in dollars per share)
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Abstract]
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Recurring and Nonrecurring [Table]
Clearance Of Investigational New Drug From FDA [Member]
Clearance Of Investigational New Drug From FDA [Member]
IND clearance from the FDA
Unrecognized Tax Benefits
Balance at the end of the year
Balance at the beginning of the year
Additional Paid-in Capital [Member]
Additional Paid-in Capital
Phase 3 clinical Trial Initiation - Second Indication [Member]
Phase 3 clinical Trial Initiation - Second Indication [Member]
Phase 3 clinical trial initiation - second indication
Advance Future Royalties, Minimum Global Net Sales, Rate
Advance Future Royalties, Minimum Global Net Sales, Rate
Settlement agreement rate
Measurement Frequency [Domain]
Measurement Frequency [Domain]
Share Repurchase Program, Authorized, Amount
Authorized repurchase amount
Statement of Income Location, Balance [Axis]
Statement of Income Location, Balance [Axis]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Trading Symbol
Trading Symbol
Jemperli Royalty Monetization Agreement Cash Milestone One [Member]
Jemperli royalty monetization agreement cash milestone one [ember]
Jemperli Royalty Monetization Agreement, Cash Milestone One
Director [Member]
Director
Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Shares Issuable
Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Shares Issuable
Number of shares issuable (in shares)
Employee-related Liabilities, Current
Accrued compensation and related expenses
Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount
Permanent items, Amount
Net Cash Provided by (Used in) Financing Activities [Abstract]
CASH FLOWS FROM FINANCING ACTIVITIES:
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Expected term (in years)
Fair Value, Recurring [Member]
Recurring
Lessee, Operating Lease, Liability, to be Paid
Total minimum payments required
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Less: imputed interest
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
R&D credits, Percent
R&D credits, Percent
Equity Components [Axis]
Equity Components [Axis]
JEMPERLI Royalty Monetization Agreement
JEMPERLI Royalty Monetization Agreement [Member]
JEMPERLI Royalty Monetization Agreement
Research and Development Expense (Excluding Acquired in Process Cost)
Research and development
Nonoperating Income (Expense)
Total other (expense) income, net
Effective Income Tax Rate Reconciliation Nondeductable Executive Compensation Amount
Effective Income Tax Rate Reconciliation Nondeductable Executive Compensation Amount
Executive compensation, Amount
Equity Component [Domain]
Equity Component [Domain]
Liabilities Related To Sale Of Future Royalties
Liabilities Related To Sale Of Future Royalties [Line Items]
Liabilities Related To Sale Of Future Royalties [Line Items]
Deferred Tax Assets, Deferred Income
Deferred Zejula royalty revenue
Auditor Information [Abstract]
Auditor Information [Abstract]
Document Annual Report
Document Annual Report
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures
Issuance of common stock upon vesting of restricted stock units (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Award expiration period (in years)
Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
Effective Income Tax Rate Reconciliation, Tax Contingency, Amount, Total
Change in unrecognized tax benefits, Amount
Maximum [Member]
Maximum
Statistical Measurement [Axis]
Statistical Measurement [Axis]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Exercises (in dollars per share)
Receivables, Net, Current
Receivables from collaborative partners
Common Stock, Value, Issued
Common stock, $0.001 par value, 500,000 shares authorized, 28,019 shares and 30,473 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Aggregate intrinsic value, restricted stock units expected to vest
Consolidation, Policy [Policy Text Block]
Basis of Consolidation
Underwriting Agreement
Underwriting Agreement [Member]
Underwritings
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Other comprehensive loss:
Deferred Tax Assets, Operating Loss Carryforwards
Net operating loss carryforwards
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Tax Credit Carryforward [Axis]
Tax Credit Carryforward [Axis]
Sale of Stock, Authorized Aggregate Offering, Maximum
Sale of Stock, Authorized Aggregate Offering, Maximum
Aggregate offering of (up to)
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
State income tax, net of federal benefit, Percent
Entity Public Float
Entity Public Float
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Expected volatility
Preferred Stock, Shares Authorized
Preferred stock, shares authorized (in shares)
Milestone Agreements
Milestone Agreements [Member]
Milestone Agreements
2018 and after
Tax Year 2018 And After [Member]
Tax year 2018 and after.
Payment, Tax Withholding, Share-Based Payment Arrangement
Payment for net share settlement of equity awards
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
Available for sale investments
Gross Unrealized Losses
Employee Stock [Member]
ESPP
Entity Registrant Name
Entity Registrant Name
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Gross Unrealized Losses
Entity Voluntary Filers
Entity Voluntary Filers
Treasury Stock, Shares, Acquired
Total number of shares purchased (in shares)
Deferred Revenue Arrangement [Line Items]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other Nonoperating Income (Expense)
Other income (expense), net
Other Nonoperating Income (Expense), Total
Additional Paid in Capital
Additional paid in capital
Subsequent Events [Abstract]
Subsequent Events [Abstract]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Income Tax Expense (Benefit)
Income tax (benefit) expense
Income tax expense (benefit)
Provision for income taxes
State income tax (benefit) expense
(Provision) benefit for income taxes
First Biologics License Application Approval Second Indication
First Biologics License Application Approval Second Indication [Member]
First BLA approval - second indication
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Payments to Acquire Productive Assets
Cash payment
Repurchase Of Common Stock Incurred But Not Yet Paid
Repurchase Of Common Stock Incurred But Not Yet Paid
Amounts accrued for repurchase of common stock
Proceeds from Issuance of Common Stock
Proceeds from issuance of common stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentration of Credit Risk
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive (loss) gain
Milestones Yet To Be Recognized
Milestones Yet To Be Recognized [Member]
Milestones that may be recognized in the future
Payments to Acquire Property, Plant, and Equipment
Purchases of property and equipment
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Granted (in shares)
ANB033
ANB033 [Member]
ANB033
Assets
Total assets
Property, Plant and Equipment [Table]
Property and Equipment, Net [Table]
Income Tax Paid, State and Local, after Refund Received
Income Tax Paid, State and Local, after Refund Received, Total
State income taxes paid
State
Schedule of Income Taxes Paid, Net of Refunds Received
Schedule Of Income Taxes Paid [Table Text Block]
Schedule of income taxes paid.
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Weighted average remaining contractual term, options exercisable
Income Statement [Abstract]
Income Statement [Abstract]
Collaborative Arrangement Costs
Collaborative arrangement costs.
Transaction costs expensed
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Decrease related to prior year tax positions
Share-Based Payment Arrangement [Policy Text Block]
Stock-Based Compensation
Shares sold (in shares)
Sale of Stock, Number of Shares Issued in Transaction
Stock Issued During Period, Shares, New Issues
Issuance of common stock (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Released (in shares)
Earnings Per Share, Diluted
Diluted (in dollars per share)
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Schedule of Segment Revenue, Loss and Significant Expenses
Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation
Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation
Executive compensation, Percent
Title and Position [Domain]
Title and Position [Domain]
Asset Acquisition [Axis]
Asset Acquisition [Axis]
City Area Code
City Area Code
Royalty Agreement, Up To $1. 0 billion
Royalty Agreement, Up To $1. 0 billion [Member]
Royalty Agreement, up To $1. 0 billion
Auditor Name
Auditor Name
Stock Awards
Stock Awards [Member]
Stock awards
Advance Future Royalties, Payment
Advance Future Royalties, Payment [Axis]
Advance Future Royalties, Payment[Axis]
Filing Of Biologics License Application Second Indication
Filing Of Biologics License Application Second Indication [Member]
Filing of the first BLA - second indication
Counterparty Name [Domain]
Counterparty Name [Domain]
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Research credits, Amount
Advance Future Royalties, Payment [Domain]
Advance Future Royalties, Payment [Domain]
Advance Future Royalties, Payment [Domain]
Operating Lease, Weighted Average Remaining Lease Term
Weighted average remaining lease term (in years)
Segment Reporting Information [Line Items]
Segment Reporting Information [Line Items]
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents
Property, Plant and Equipment, Net
Property and equipment, net
Total property and equipment, net
Operating Income (Loss)
Income (loss) from operations
Retained Earnings [Member]
Accumulated Deficit
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Write-off
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Write-off
Deferred tax write-off, Percent
Jemperli Royalty Monetization Agreement
Jemperli Royalty Monetization Agreement [Member]
Jemperli Royalty Monetization Agreement
Share-Based Payment Arrangement, Noncash Expense
Stock-based compensation
Asset Acquisition, Consideration Transferred
Total transaction
Payments of Stock Issuance Costs
Payments for offering costs, net
Drug Supply [Member]
Drug supply.
Drug Supply
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months
Less than 12 Months, Fair Value
Operating Lease, Weighted Average Discount Rate, Percent
Weighted-average discount rate (as a percent)
Operating Lease, Liability, Noncurrent
Operating lease liability, net of current portion
Fair Value, Inputs, Level 1 [Member]
Quoted Market Prices for Identical Assets (Level 1)
Class of Stock [Line Items]
Class of Stock [Line Items]
Net Cash Provided by (Used in) Financing Activities
Net cash (used in) provided by financing activities
Lease, Cost [Table Text Block]
Schedule of Non-Cancellable Office Lease Costs
Auditor Location
Auditor Location
Nonoperating Income (Expense) [Abstract]
Other (expense) income, net:
Deferred Tax Assets, Lease Liability
Deferred Tax Assets, Lease Liability
Lease liability
AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab)
AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) [Member]
TIM-3 (GSK4069889/Cobolimab)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share
Income Tax Jurisdiction [Domain]
Income Tax Jurisdiction [Domain]
Debt Securities, Available-for-Sale [Table]
Debt Securities, Available-for-sale [Table]
Entity Interactive Data Current
Entity Interactive Data Current
Statement of Income Location, Balance [Domain]
Statement of Income Location, Balance [Domain]
Net Cash Provided by (Used in) Operating Activities [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Income Tax Reconciliation Deferred Tax Write-off
Income Tax Reconciliation Deferred Tax Write-off
Deferred tax write-off, Amount
Biopharma Company [Member]
Biopharma Company.
Biopharma
Fourth Commercial Sales Milestone
Fourth Commercial Sales Milestone [Member]
Fourth commercial sales milestone
Class of Treasury Stock [Table Text Block]
Schedule of Stock Repurchase Activity
Components of Deferred Tax Liabilities [Abstract]
Deferred Tax Liabilities:
Entity Tax Identification Number
Entity Tax Identification Number
Number of Milestones Acheived
Number of milestones acheived.
Number of milestone
Business Separation Capitalization Period
Business Separation Capitalization Period.
Business separation, expected period
Interest Income, Other
Interest income
Local Phone Number
Local Phone Number
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Unrecognized compensation cost
Auditor Opinion [Text Block]
External Expenses
External Expenses [Member]
External
Accounting Policies [Abstract]
Accounting Policies [Abstract]
Disaggregation of Revenue [Line Items]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax
Collaboration revenue
Lessee, Operating Lease, Liability, to be Paid, Year Four
2029
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Shares reserved for future award grants (in shares)
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Weighted average period remaining for amortization of unrecognized compensation cost (in years)
Office Equipment [Member]
Office furniture and equipment
Accrued Professional Fees, Current
Accrued professional fees and other expenses
Stock, Class of Stock [Table]
Stock, Class of Stock [Table]
Entity Emerging Growth Company
Entity Emerging Growth Company
Deferred Tax Assets, Net, Before Valuation Allowance
Deferred Tax Assets, Net, Before Valuation Allowance
Net deferred tax assets
Tax Credit Carryforward, Name [Domain]
Tax Credit Carryforward, Name [Domain]
Collaboration Revenue
Collaboration Revenue [Member]